Tokyo Tape
Sign in
← Fukuda Denshi

Quarterly report · Q2

6960.TEDINET S100PJZR
Period2022-04-01 → 2022-09-30
Filed2022-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥62.6bn2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥132.1bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥61.7bn2021-04-01 → 2021-09-30Cons.Net sales
Operating income¥11.1bn2022-04-01 → 2022-09-30Cons.Operating income
Operating income¥10.4bn2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income¥11.7bn2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income¥23.4bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥10.7bn2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax¥11.8bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax¥11.0bn2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)¥8.1bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥16.2bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥7.5bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income¥8.1bn2022-04-01 → 2022-09-30Cons.Profit loss
Net income¥7.5bn2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥196.9bnat 2022-09-30Cons.Assets
Total assets¥195.5bnat 2022-03-31Cons.Assets
Total assets¥183.1bnat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥41.7bnat 2022-09-30Cons.Liabilities
Total liabilities¥45.6bnat 2022-03-31Cons.Liabilities
Net assets / equity¥155.1bnat 2022-09-30Cons.Net assets
Net assets / equity¥149.9bnat 2022-03-31Cons.Net assets
Net assets / equity¥142.9bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥66.4bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥64.1bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥63.4bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥61.0bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥52.5bnat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥53.6bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow¥11.3bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥23.1bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥7.7bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥6.5bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥10.8bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥5.6bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥3.1bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥4.8bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥3.1bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥536.852022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥348.312022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥1,072.382021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥495.612021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥312.32021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio78.8%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio76.7%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio78.0%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 30
SegmentItemPeriodValue
jpcrp040300-q2r_E02304-000Consumables And Other Productsreportable segmentrevenue2022-04-01 → 2022-09-30¥17.1bn
jpcrp040300-q2r_E02304-000Consumables And Other Productsreportable segmentrevenue external2022-04-01 → 2022-09-30¥17.1bn
jpcrp040300-q2r_E02304-000Consumables And Other Productsreportable segmentsegment profit2022-04-01 → 2022-09-30¥2.1bn
jpcrp040300-q2r_E02304-000Medical Treatment Equipmentreportable segmentrevenue2022-04-01 → 2022-09-30¥26.9bn
jpcrp040300-q2r_E02304-000Medical Treatment Equipmentreportable segmentrevenue external2022-04-01 → 2022-09-30¥26.9bn
jpcrp040300-q2r_E02304-000Medical Treatment Equipmentreportable segmentsegment profit2022-04-01 → 2022-09-30¥6.0bn
jpcrp040300-q2r_E02304-000Patient Monitoring Equipmentreportable segmentrevenue2022-04-01 → 2022-09-30¥5.2bn
jpcrp040300-q2r_E02304-000Patient Monitoring Equipmentreportable segmentrevenue external2022-04-01 → 2022-09-30¥5.2bn
jpcrp040300-q2r_E02304-000Patient Monitoring Equipmentreportable segmentsegment profit2022-04-01 → 2022-09-30¥881m
jpcrp040300-q2r_E02304-000Physiological Diagnostic Equipmentreportable segmentrevenue2022-04-01 → 2022-09-30¥13.4bn
jpcrp040300-q2r_E02304-000Physiological Diagnostic Equipmentreportable segmentrevenue external2022-04-01 → 2022-09-30¥13.4bn
jpcrp040300-q2r_E02304-000Physiological Diagnostic Equipmentreportable segmentsegment profit2022-04-01 → 2022-09-30¥2.1bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥62.6bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥62.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥11.1bn
jpcrp040300-q2r_E02304-000Consumables And Other Productsreportable segmentrevenue2021-04-01 → 2021-09-30¥16.2bn
jpcrp040300-q2r_E02304-000Consumables And Other Productsreportable segmentrevenue external2021-04-01 → 2021-09-30¥16.2bn
jpcrp040300-q2r_E02304-000Consumables And Other Productsreportable segmentsegment profit2021-04-01 → 2021-09-30¥2.2bn
jpcrp040300-q2r_E02304-000Medical Treatment Equipmentreportable segmentrevenue2021-04-01 → 2021-09-30¥27.0bn
jpcrp040300-q2r_E02304-000Medical Treatment Equipmentreportable segmentrevenue external2021-04-01 → 2021-09-30¥27.0bn
jpcrp040300-q2r_E02304-000Medical Treatment Equipmentreportable segmentsegment profit2021-04-01 → 2021-09-30¥5.5bn
jpcrp040300-q2r_E02304-000Patient Monitoring Equipmentreportable segmentrevenue2021-04-01 → 2021-09-30¥6.2bn
jpcrp040300-q2r_E02304-000Patient Monitoring Equipmentreportable segmentrevenue external2021-04-01 → 2021-09-30¥6.2bn
jpcrp040300-q2r_E02304-000Patient Monitoring Equipmentreportable segmentsegment profit2021-04-01 → 2021-09-30¥1.0bn
jpcrp040300-q2r_E02304-000Physiological Diagnostic Equipmentreportable segmentrevenue2021-04-01 → 2021-09-30¥12.3bn
jpcrp040300-q2r_E02304-000Physiological Diagnostic Equipmentreportable segmentrevenue external2021-04-01 → 2021-09-30¥12.3bn
jpcrp040300-q2r_E02304-000Physiological Diagnostic Equipmentreportable segmentsegment profit2021-04-01 → 2021-09-30¥1.6bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-09-30¥61.7bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-09-30¥61.7bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-09-30¥10.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 528
ItemContextValueUnit
Directors compensations salaries and allowances sgaPrior1YTDDuration8184000000JPY
Directors compensations salaries and allowances sgaCurrentYTDDuration8383000000JPY
Provision for bonuses sgaPrior1YTDDuration2204000000JPY
Provision for bonuses sgaCurrentYTDDuration2256000000JPY
Provision for directors retirement benefits sgaPrior1YTDDuration24000000JPY
Provision for directors retirement benefits sgaCurrentYTDDuration30000000JPY
Retirement benefit expenses sgaPrior1YTDDuration562000000JPY
Retirement benefit expenses sgaCurrentYTDDuration590000000JPY
Provision for directors bonuses sgaPrior1YTDDuration205000000JPY
Provision for directors bonuses sgaCurrentYTDDuration131000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E02304-000PhysiologicalDiagnosticEquipmentReportableSegmentsMember12268000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E02304-000PatientMonitoringEquipmentReportableSegmentsMember6217000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E02304-000MedicalTreatmentEquipmentReportableSegmentsMember27028000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E02304-000ConsumablesAndOtherProductsReportableSegmentsMember16177000000JPY
Revenues from external customersPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember61692000000JPY
Revenues from external customersPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YTDDuration61692000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E02304-000PhysiologicalDiagnosticEquipmentReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E02304-000PatientMonitoringEquipmentReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E02304-000MedicalTreatmentEquipmentReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E02304-000ConsumablesAndOtherProductsReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember－JPY
Transactions with other segmentsPrior1YTDDuration_ReconcilingItemsMember－JPY
Transactions with other segmentsPrior1YTDDuration－JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E02304-000PhysiologicalDiagnosticEquipmentReportableSegmentsMember12268000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E02304-000PatientMonitoringEquipmentReportableSegmentsMember6217000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E02304-000MedicalTreatmentEquipmentReportableSegmentsMember27028000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E02304-000ConsumablesAndOtherProductsReportableSegmentsMember16177000000JPY
Net salesPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember61692000000JPY
Net salesPrior1YTDDuration_ReconcilingItemsMember－JPY
Net salesPrior1YTDDuration61692000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E02304-000PhysiologicalDiagnosticEquipmentReportableSegmentsMember1600000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E02304-000PatientMonitoringEquipmentReportableSegmentsMember1001000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E02304-000MedicalTreatmentEquipmentReportableSegmentsMember5528000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E02304-000ConsumablesAndOtherProductsReportableSegmentsMember2249000000JPY
Operating incomePrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember10380000000JPY
Operating incomePrior1YTDDuration_ReconcilingItemsMember－JPY
Operating incomePrior1YTDDuration10380000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E02304-000PhysiologicalDiagnosticEquipmentReportableSegmentsMember13417000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E02304-000PatientMonitoringEquipmentReportableSegmentsMember5202000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E02304-000MedicalTreatmentEquipmentReportableSegmentsMember26924000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E02304-000ConsumablesAndOtherProductsReportableSegmentsMember17084000000JPY
Revenues from external customersCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember62628000000JPY
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration62628000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E02304-000PhysiologicalDiagnosticEquipmentReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E02304-000PatientMonitoringEquipmentReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E02304-000MedicalTreatmentEquipmentReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E02304-000ConsumablesAndOtherProductsReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass